Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · TB-500Mixed
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
A narrative review rather than new data, and the authors are explicit that the human evidence base for these peptides remains limited and largely preclinical. It is useful mainly as a map of proposed mechanisms and regulatory status for BPC-157, TB-500 and GHK-Cu in one place. Narrative reviews carry no systematic search or risk-of-bias assessment, so read the enthusiasm in the framing with that limit in mind. Regulatory status is unchanged: these remain unapproved for the indications discussed.
Current pain and headache reportsn=——Aug 24, 2026 - Study · TB-500Weak / none
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
This is the most direct literature audit yet of the peptides that dominate recovery marketing, and its finding is a familiar one: the animal work is interesting, the human work is thin. Sixty-seven percent of the included publications were preclinical, and the clinical studies that exist are heterogeneous in dose and route of administration. Worth citing on our BPC-157, TB-500, CJC-1295, ipamorelin and GHK-Cu pages as the current state of evidence, alongside the cardiovascular and metabolic risks the authors document.
The American journal of sports medicinen=——Aug 11, 2026 - Study · TB-500Weak / none
PEGylated thymosin β4 is a thiol-site-specific prodrug treating myocardial infarction in vivo.
This is a preclinical drug-development study of full-length thymosin β4 — the parent molecule of the TB-500 fragment tracked here — reformulated as a PEGylated, thiol-site-specific prodrug (PEG-rTβ4) to extend its circulating half-life. In a rodent myocardial-infarction model, researchers reported the long-circulating construct was associated with reduced myocardial remodeling, improved cardiac function, greater new-vessel formation and less cell death, signaling through an Akt/Bcl-2/caspase-3 pathway. The work is engineering-forward: its central claim is druggability (supply, purity, half-life), not human efficacy. These are preclinical in-vivo findings; human data are needed before clinical conclusions can be drawn — and the authors themselves note no thymosin β4 drug has been approved despite a decade of trials. Weight this as an early manufacturing-and-mechanism signal for the thymosin β4 class, not as evidence in people.
Bioengineering & translational medicinen=—AnimalJul 1, 2026 - Study · KisspeptinWeak / none
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
This study is not a clinical or pharmacological investigation — it is a doping-control analytical methods paper, and should be read as such. Researchers developed and validated a streamlined workflow capable of detecting 54 prohibited substances, including BPC-157 and TB-500, across dried blood spots, serum, and plasma using a single microextraction step followed by liquid chromatography coupled with high-resolution mass spectrometry. The analytical performance was satisfactory by laboratory standards: detection limits ranged from 0.05–1.25 ng/mL, no carry-over was observed, and matrix effects were modest (5–33%). Notably, dried blood spot matrices preserved all compounds for the full study duration under non-refrigerated conditions — a meaningful practical advantage for anti-doping sample logistics. For readers tracking BPC-157 and TB-500 specifically: the stability data are striking. Both peptides showed complete degradation in serum within one week at room temperature or refrigerator temperature — a finding with direct implications for detection windows in anti-doping contexts. Dried matrices retained detectability throughout. This paper contributes nothing to the...
The Analystn=——Jun 22, 2026 - Study · TB-500Weak / none
Reparative Outcomes in Corneal Infection: Linking Adjunctive Tβ4 Treatment to Nerve Regeneration and Visual Function.
A mouse study of thymosin beta-4 (the parent peptide of TB-500) as an add-on to the antibiotic ciprofloxacin in Pseudomonas bacterial keratitis. Researchers report that the Tβ4-plus-ciprofloxacin combination was associated with better visual acuity, contrast sensitivity, corneal sensitivity and nerve regeneration than antibiotic or Tβ4 alone, restoring nerve density toward uninfected levels. The novel angle is functional visual and nerve endpoints rather than just wound closure, which strengthens it relative to structure-only studies. Key caveats: this is a rodent infection model with small groups, it tests native Tβ4 (not the TB-500 synthetic fragment community users inject), and the benefit appears only in combination with an antibiotic, not as monotherapy. Tβ4's ophthalmic wound-healing signal is one of its more developed lines, but this specific finding is preclinical. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Investigative ophthalmology & visual sciencen=—AnimalJun 1, 2026